

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

021286/027 633

Application Number

09/844,684

Applicant(s)

Mikayama, et al.

Filing Date

April 27, 2001

Group Art Unit

1645

64Y

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
M		5,677,165	10/14/97	de Boer, et al.			May 28, 1993
		5,786,456	7/28/98	Ledbetter, et al.			Sept. 20, 1993
		5,801,227	9/1/98	Fanslow, III, et al.			Sept. 8, 1995
M		5,874,082	2/23/99	de Boer			Feb. 23, 1996

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO
M		WO 99/42075	08/26/99	PCT			✓	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

M		Tomizuka, et al., "Double trans-chromosomal mice: Maintenance of two individual human chromosome fragments containing Ig heavy and kappa loci and expression of fully human antibodies", PNAS, Jan. 18, 2000, Vol. 97, no. 2.
M		Schoenberger, et al., "T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions", Nature, Vol. 393, June 4, 1998.

EXAMINER

PHUUPG smbz 6/13/03

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

021286/027 633

Application Number

09/844,684

Applicant(s)

Mikayama, et al.

Filing Date

4/27/01

Group Art Unit

1643 1644

*EXAMINER

INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Stamenkovic, et al., "A B-lymphocyte activation molecule related to the nerve growth factor receptor and inuced by cytokines in carcinomas", The EMBO Journal, Vol. 8, no. 5, pp. 1403-1410, 1989.

Clark, et al., "CDw40 and BLCa-specific monoclonal antibodies detect two distinct molecules which transmit progression signals to human B lymphocytes*", Eur. J. Immunol., 1988, 18: 451-457.

Ledbetter, et al., "Augmentation of Normal and Malignant B Cell Proliferation by Monoclonal Antibody to the B Cell-Specific Antigen BP50 (CDW40), The Journal of Immunology, Vol. 138, pp. 788-794, No. 3, February 1, 1987.

Clark, et al., "Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50", Proc. Natl. Acad. Sci. USA, Vol. 83, pp. 4494-4498, June 1986.


Paulie, et al., "A p50 surface antigen restricted to human urinary bladder carcinomas and B lymphocytes", Cancer Immunology Immunother, (1985), 20: 23-28.

EXAMINER

GAMGEL 6/13/03

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Atty.
Dkt. No.

M#

Client Ref.

021286-0276339

Applicant: Mikayama, T., et al.

Appln. No.: 09/844,684

Filing Date: April 27, 2001

Examiner: Philip Gambel

Group Art Unit: 1644

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Date: December 9, 2002

Page

1

of

1

U.S. PATENT DOCUMENTS

Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
PL	AR	5,786,456	07/1998	Ledbetter, et al.	530	388.73	09/20/93
	BR	6,004,552	12/1999	de Boer, et al.	424	144.1	06/05/95
	CR	6,051,228	04/2000	Aruffo, et al.	424	144.1	02/19/98
	DR						
	ER						
	FR						
	GR						

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name		English Abstract		Translation Readily Available	
							Enclosed	No	Enclose	No
	HR	WO 00/75348A1	12/2000	PCT	Siegall, Clay B., et al.	C12N 15/63				
	IR	WO 01/83755 A2	11/2001	PCT	Mikayama, T., et al.	C12N 15/13				
	JR	WO 01/83755 A3	11/2001	PCT	Mikayama, T., et al.	C12N 15/13				
M	KR	WO 02/28904 A2	04/2002	PCT	Chu, K., et al.	C07K 16/28				
	LR									
	MR									
	NR									
	OR									
	PR									
	QR									

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)


	RR									
	SR									
	TR									
	UR									
	VR									
	WR									

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Gambel 6/13/03



Atty.
Dkt. No.

M#

Client Ref.

021286-0276339

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Applicant: Mikayama, T., et al.

Appln. No.: 09/844,684

Filing Date: April 27, 2001

Date: March 20, 2003

Page 1 of 3

Examiner: Philip Gambel

Group Art Unit: 1644

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
AR						
BR						

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
						Enclosed	No	Enclose	No
✓	CR	WO 91/09115	06/1991	PCT	Banchereau	Y			
	DR	WO 96/33735	10/1996	PCT	Kucherlapati	Y			
	ER	WO 96/34096	10/1996	PCT	Kucherlapati	Y			
	FR	WO 99/61051	12/1999	PCT	Segal	Y			
	GR	WO 00/00156	01/2000	PCT	Wade	Y			
	HR	WO 00/75348 A1	12/2000	PCT	Siegall	Y			
	IR	WO 01/24823	04/2001	PCT	Keting	Y			
	JR	WO 01/56603	08/2001	PCT	Thomas	Y			
	KR	WO 02/28904	04/2002	PCT	Chu	Y			
	LR	EP 0945 465 A1	09/1999	EP	De Boer	Y			
	MR	EP 0972 445 A1	01/2000	EP	Tomizuka	Y			

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

NR	Kwekkeboom, et al., "Helper effector function of human T cells stimulated by anti-CD3 mAb can be enhanced by co-stimulatory signals and is partially dependent on CD40-CD40 ligand interaction," <u>Eur. J. Immunol.</u> (1994), Vol. 24, pp. 508-517.	Y			
OR	Hasbold, et al., "Cell division number regulates IgG1 and IgE switching of B cells following stimulation by CD40 ligand and IL-4," <u>Eur. J. Immunol.</u> (1998), Vol. 28, pp. 1040-1051.	Y			
PR	Pound, et al., "Minimal cross-linking and eptiope requirements for D40-dependent suppression of apoptosis contrast with those for promotion of the cell cycle and homotypic adhesions in human B cells," <u>Int'l Immunol.</u> (1999), Vol. 11, No. 1, pp. 11-20.	Y			
QR	Francisco, et al., "Agonistic Properties and <i>in Vivo</i> Antitumor of the Anti-CD40 Antibody SGN-14," <u>Cancer Research</u> , (June 15, 2000), Vol. 60, pp. 3225-3231.	Y			
RR	Romano, et al., "Triggering of CD40 Antigen Inhibits Fludarabine-Induced Apoptosis in B Chronic Lymphocytic Leukemia Cells," <u>Blood</u> , (August 1, 1998) Vol. 98, No. 3, pp. 990-995.	Y			
SR	Hirano, et al., "Inhibition of Human Breast Carcinoma Growth by a Soluble Recombinant Human CD40 Ligand," <u>Blood</u> , (May 1, 1999), Vol. 93, No. 9, pp. 2999-3007.	Y			

Gambel 6/13/03

TR	Francisco, et al., "Construction, Expression, and Characterization of G28-5 sFv, a Single-chain Anti-CD40 Immunotoxin Containing the Ribosome-inactivating Protein Bryodin 1," <u>Journal of Biological Chemistry</u> , (Sept. 26, 1997), Vol. 272, No. 39, pp. 24165-24169.	Y			
WR	Maxwell, et al., "Contrasting the Roles of Costimulation and the Natural Adjuvant Lipopolysaccharide During the Induction of T Cell Immunity," <u>J. Immunol.</u> , (May 1, 2002), Vol. 168, No. 9, pp. 4372-4381.	Y			
VR	Simonsson, et al., "Single, Antigen-Specific B Cells Used to Generate Fab Fragments Using CD40-Mediated Amplification or Direct PCR Cloning," <u>BioTechniques</u> , (1995), Vol. 18, No. 5, pp. 862-869.	Y			
WR	Dullforce, et al., "Enhancement of T cell-independent immune responses <i>in vivo</i> by CD 40 antibodies," <u>Nature Medicine</u> , (Jan. 1998), Vol. 4, No. 1, pp.88 - 91.	Y			
XR	Erickson, et al., "Short-circuiting long-lived humoral immunity by the heightened engagement of CD40," <u>The J. of Clinical Investigation</u> , (March, 2002), Vol. 109, No. 5, pp. 613-620.	Y			
YR	Murphy, et al., "Antibodies to CD40 Prevent Epstein-Barr Virus- Mediated Human B-Cell Lymphomagenesis in Severe Combined Immune Deficient Mice Given Human Peripheral Blood Lymphocytes," <u>Blood</u> , (September 1, 1995), Vol. 86, No. 5, pp. 1946-1953.	Y			
ZR	Funakoshi, et al., "Differential In Vitro and In Vivo Antitumor Effects Mediated by Anti-CD40 and Anti-CD20 Monoclonal Antibodies Against Human B-Cell Lymphomas," <u>J. of Immunology</u> , (1996) Vol. 19, No. 2, pp. 93-101.	Y			
AAR	Schwabe, et al., "Modulation of Soluble CD40 Ligand Bioactivity with Anti-CD40 Antibodies," <u>Hybridoma</u> , (1997), Vol. 16, No. 13, pp. 217-226.	Y			
BBR	Funakoshi, et al., "Inhibition of Human B-Cell Lymphoma Growth by CD40 Stimulation," <u>Blood</u> , (May 15, 1994), Vol. 83, No. 10, pp. 2787-2794.	Y			
CCR	Rolink, et al., "The SCID but Not the RAG-2 Gene Product Is Required for Sμ-Sε Heavy Chain Class Switching," <u>Immunity</u> , (October, 1996) Vol. 5, pp. 319-330.	Y			
DDR	Kwekkeboom, et al., "CD40 plays an essential role in the activation of human B cells by murine EL4B5 cells," <u>Immunology</u> , (1993), Vol. 79, pp. 439-444.	Y			
EER	Zhou, et al., "An Agonist Anti-Human CD40 Monoclonal Antibody that Induces Dendritic Cell Formation and Maturation and Inhibits Proliferation of a Myeloma Cell Line," <u>Hybridoma</u> , Vol. 18, No. 6, 1999, pp. 471-478.	Y			
FFR	Heath, et al., "Monoclonal antibodies to murine CD40 define two distinct functional epitopes," <u>Eur. J. Immunology</u> , (1994) Vol. 24, pp. 1828-1834.	Y			
GGR	Mazzei, et al., "Recombinant Soluble Trimeric CD40 Ligand Is Biologically Active," <u>Journal of Biological Chemistry</u> , (March 31, 1995), Vol. 270, No. 13, pp. 7025-7028.	Y			
HHR	Hasbold, et al., "Properties of mouse CD40: cellular distribution of CD40 and B cell activation by monoclonal anti-mouse CD40 antibodies," <u>Eur. J. Immunology</u> , (1994) Vol. 24, pp. 1835-1842.	Y			
IIR	Weng, et al., "Human Anti-CD40 Antagonistic Antibodies Inhibit the Proliferation of Human B Cell Non-Hodgkin's Lymphoma," Program of the 43 rd Annual Meeting of The American Society of Hematology, (December 7-11, 2001), Abstract No. 1947, page 466a.	Y			
JJR	Ledbetter, et al., "Agonistic Activity of a CD40-Specific Single-Chain Fv Constructed from the Variable Regions of mAb G28-5," <u>Critical Reviews in Immunology</u> , (1997), Vol. 17, pp. 427-435.	Y			
KKR	de Boer, et al., "Generation of monoclonal antibodies to human lymphocyte cell surface antigens using insect cells expressing recombinant proteins," <u>Journal of Immunological Methods</u> , (1992) Vol. 152, pp. 15-23.	Y			
LLR	Karlsson, et al., "Selection of human single chain antibodies against CD-40," <u>Immunology Letters</u> , Vol. 73, Nos. 2,3, Abstract No. 358.	Y			
MMR	Sotomayor, et al., "Conversion of tumor-specific CD4 T-cell tolerance to T-cell priming through <i>in vivo</i> ligation of CD40," <u>Nature</u> , (July, 1999), Vol. 398, No. 7, pp. 780-787.	Y			

OIP

 MAR 24 2003

 PHARM & T, ADI-MAL, CALIF.

RECEIVED

 MAR 25 2003

 TECH CENTER 1600/2800

Gunnar 6/13/03

NR	Diehl, et al., "CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy," <u>Nature Medicine</u> , (July 1999) Vol. 5, No. 7, pp. 774-779.	Y			
OR	Schoenberger, et al., "T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions," <u>Nature</u> , (June 4, 1998), Vol. 393, pp.480-483.	Y			
OR	van Mierlo, et al. "CD40 stimulation leads to effective therapy of CD40-tumors through induction of strong systemic cytotoxic T lymphocyte immunity," <u>PNAS</u> , (April 16, 2002) Vol. 99, No. 8, pp. 5561-5566.	Y			
OR	An, et al., "Ligation of CD40 Potentiates Fas-Mediated Activation of the Cysteine Protease CPP32, Cleavage of Its Death Substrate PARP, and Apoptosis in Ramos - Burkitt Lymphoma B Cells," <u>Cellular Immunology</u> , (1997) Vol. 181, pp. 139-152.	Y			
RR	Barr, et al., "Functional activity of CD40 antibodies correlates to the position of binding relative to CD154," <u>Immunology</u> , (2001) Vol. 102, pp. 39-43.	Y			
SS	Baccam, et al., "Membrane-bound CD154, but not CD40-specific antibody, mediates NF- κ B-independent IL-6 production in B cells," <u>Er. J. Immunol.</u> , (1999), Vol. 29, pp. 3855-3866.	Y			
TT	Kedl, et al., "CD40 stimulation accelerates deletion of tumor specific CD8+ T cells in the absence of tumor-antigen vaccination," <u>PNAS</u> , (September 11, 2001) Vol. 98, No. 19, pp. 10811-10816.	Y			
UU	Tomizuka, et al., "Double trans-chromosomic mice: Maintenance of two individual human chromosome fragments containing Ig heavy and κ loci and expression of fully human antibodies," <u>PNAS</u> , (January 18, 2000) Vol. 97, No. 2, pp. 722-727.	Y			
VV	Boon, et al., "Preclinical assessment of anti-CD40 Mab 5D12 in cynomolgus monkeys," <u>Toxicology</u> , (2002), Vol. 174, pp. 53-65.	Y			
WW					
XX					
YY					
ZZ					

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

GAMCZ 6/13/03

RECEIVED
MAR 25 2003
TECH CENTER 1600/2900